Seattle-based Phase Genomics has been awarded a $1.7 million grant from the National Institutes of Health. The funding will go toward creating a platform for the discovery of novel viruses that can then be used to develop new therapeutics.
The company aims to use its sequencing-based proximity ligation, or Hi-C, technology to develop a reagent kit and accompanying analytical software. This will provide insight into antimicrobial resistance and help in the development of phage therapies for the treatment of infectious diseases. The platform is expected to be commercially available by mid-2021.